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MicroRNAs (miRNAs), first discovered in the year 1993 in the nematode 
C.  elegans, are small, approximately 22-nucleotide-long, non-coding RNAs that 
regulate gene expression. Cellular miRNAs have been implicated in the control of 
many biological processes, and their dysregulation is associated with different dis-
eases. They can be significantly up/downregulated upon infection or disease, serv-
ing as excellent biomarkers and therapeutic targets. Several human DNA viruses, 
including many herpesviruses, have now been reported to encode viral miRNAs. 
There are a variety of possible interactions and mechanisms of viral microRNAs 
(vmiRNAs) which are yet to be remains obscure. Viral miRNAs can function as 
orthologs of cellular miRNAs and regulate their expression. Additionally, viruses 
have also developed vmiRNA mechanisms to avoid being targeted by the host 
miRNAs. Herpes Simplex Viruses (HSV-1 & HSV-2) cause genital and oral herpes, 
establishing lifelong latent infections in their hosts, and it is one of the most preva-
lent sexually transmitted infections (STIs) worldwide. vmiRNAs play essential 
roles in Herpesvirus biology. In this chapter, we will discuss the current knowledge 
about miRNAs and their role in different stages of Herpesvirus infection. It will 
also elaborate the biomarkers, therapeutic potential of these molecules, and the 
prospective areas of future research.
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1. Introduction
Eight out of the hundred reported herpesviruses, from the family herpesviridae 
(herpein meaning, “to creep”), cause lytic and latent infections in the humans. The 
human herpesviruses are classified into the alpha-, beta- and the gamma-herpesvi-
ruses, based on the range of hosts they infect. The alpha (α)-herpesviruses, involv-
ing the herpes Simplex Virus −1 (HSV-1), HSV-2 and the varicella zoster virus 
(VZV), are known to infect a broad range of hosts while having a short replication 
cycle in these hosts. The beta (β)-herpesviruses include the members, the human 
cytomegalovirus (HCMV) and the reseolo-human herpesvirus −6 and − 7, and 
infect a restricted range of hosts as compared to the α-herpesviruses while having 
a longer replication cycle within these hosts. The third group known as the gamma 
(γ)- herpesviruses, containing the Epstein–Barr virus (EBV) and the Kaposi’s sar-
coma associated herpesvirus (KSHV), have the most restricted host range amongst 
the three sub-categories of human herpesviruses [1]. As reported for the year 2016, 
13.2% of the global population aged 15 to 49 years were harboring HSV-2 within 
themselves, whereas about 66.6% amongst the 0 to 49 years aged individuals had 
HSV-1 infection [2]. Persons infected with HSV-2 are at 3 times to risk of infection 
with HIV compared to persons who are not infected with HSV-2 [3]. This may or 
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may not be due to a biological process as implied, but behavioral and the specific 
populations are vulnerable to infections with both the viruses. Both HSV-1 and 2 
have an envelope of lipid-bilayer encasing them and have a double-stranded DNA 
(~152 kb) as their genetic material. The 12 glycoproteins in the outer layer partici-
pate in the entry of the HSV into the cell. The viral genes are expressed in an orderly 
fashion with the immediate early (IE) genes expressed first, which encode the 
proteins for the regulation of the viral replication. This is followed by the expression 
of the early (E) genes, which encode for the enzymes involved in the replication 
process. Finally, the expression of the late (L) genes takes place, which encode for 
the structural proteins of HSV [4]. The completion of the replicative cycle results 
in the generation of assembled virions which are transported via the endoplasmic 
reticulum/Golgi cargo transport system to the cell membrane, where the virions are 
released by acquiring a part of the host’s cell membrane. HSV infection leads to pain 
and suffering, which although not always, may be lethal to the host. HSV-1 mainly 
causes the stromal keratitis in the eye whereas HSV-2 is responsible for genital 
lesions [4]. No vaccines against HSV are available for public use, although some 
are undergoing clinical trials. Therefore, drugs like Acyclovir, Valacyclovir and 
Famciclovir are the only therapeutic solutions available, which are associated with 
side-effects and limitations in bioavailability [5]. Thus, more suitable therapeutic 
agents, in terms of optimal bioavailability and diminished adverse effects, is the 
need of the hour.
MicroRNAs (miRNAs) on the other hand, are gaining a growing attention 
from the scientific community as the self-molecules which are the key regulators 
in infection and disease. These 20–24 nucleotides are non-protein coding RNAs 
which act post-transcriptionally to regulate the expression of the genes [6]. Since its 
discovery, miRNAs have found their significance in the diagnostics and therapeutics 
of diseases such as cancers, diabetes and infections of bacteria and viruses [7–13]. 
Thus, in this chapter, we have made an attempt to review the facts known about 
miRNAs are discuss their role in herpesvirus infection with our main focus on HSV 
infections.
2. Biogenesis of miRNAs
2.1 Canonical pathway for miRNA biosynthesis
The biological synthesis of miRNAs may be either from intragenic or intergenic 
sequences. Most of the intragenetically synthesized miRNAs are from introns 
whereas some are from exons of the protein coding genes. miRNAs are also syn-
thesized from intergenic sequences which are independent miRNA genes and 
have their own, specific promoters. There are canonical as well as non-canonical 
pathways for miRNA genesis [14] The canonical pathway for miRNA biogenesis 
marks the transcription of the primary miRNA (pri-miRNA) from the miRNA 
genes by RNA Polymerase II (RNA Pol II) in the nucleus. After the transcription the 
pri-miRNA, which can be as long as 1000 nucleotides in length, they are processed 
by a microprocessor complex consisting of an RNA-binding protein DGCR8 and an 
RNase III Drosha. Pri-miRNA methylation by methyltransferase-like 3 (METTL3) 
marks it for recognition by DGCR8 of the microprocessor complex [15] DGCR8 
recognizes the intersection of the flanking single-stranded (ss) RNA and the stem 
loop in the pri-miRNA hairpin-structure after which, the Drosha is recruited and 
involves in a cleavage process [16] This processing forms the precursor miRNAs or 
pre-miRNAs (~80 nucleotides in length) having 2 nucleotide 3′ overhangs, which 




complex. In the cytosol, the Ran GTPase- activating protein brings about the 
hydrolysis of GTP, changing the Ran conformation, thereby, releasing the pre-
miRNA bound to the XPO5 [17] After the release, the RNAse III endonuclease Dicer 
removes ~22 base pairs (bp) of the pre-miRNA terminal loop to form the mature 
miRNA duplex (Figure 1). This processing step of the miRNA allows them to be 
eligible for loading onto the Argonaute (Ago) complex of proteins which are the 
essential components of the RNA-induced Silencing Complex (RISC), therefore, 
the miRNAs mediate their action (Figure 1). The decision for the specific load-
ing of a strand of miRNA duplex on the RISC complex is made on the basis of the 
thermodynamic stability of the two strands and is accompanied by ATP hydrolysis 
[18] The strand with a lower 5′ stability or a 5’ Uracil is named as the guide strand 
(~22 nucleotides in length) and is loaded onto the Ago protein, while the strand not 
loaded onto Ago, named as the passenger strand, is cleaved by the slicer activity of 
the Ago and degraded by the ribonucleases [14, 19].
2.2 Non-canonical pathways for miRNA biosynthesis
While most of the miRNAs are generated via the canonical pathway, there are 
many which are synthesized by the non-canonical pathways. Although there may 
be many such non-canonical miRNA synthesis pathways, they use up different 
combinations of proteins that are participants of the canonical pathway. Primarily, 
there are two types of the non-canonical pathways, the Drosha/DGCR8 indepen-
dent route and the Dicer independent route. Mitrons are an example of miRNAs 
synthesized by the Drosha/DGCR8 independent pathway, where the pre-miRNAs 
Figure 1. 
Biogenesis of miRNAs: A. transcription of pri-miRNA from the miRNA gene by RNA pol II followed by 
B. Drosha/DGCR8 cleavage of the pri-miRNA to pre-miRNA. C. the pre-miRNA is then exported from 
the nucleus to the cytoplasm with the help of the Exportin 5 /ran GTP complex where D. dicer cleavage of the 
hairpin structure takes place. E. One of the strands of the miRNA duplex is loaded onto the RISC, via the 
ago protein which causes the F. repression of the gene expression by base complementarity-induced mRNA 
degradation or translation repression.
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generated are similar to the Dicer substrates [20] Here, Exponin-1 needs to trans-
port the miRNA transcripts to the cytosol without Drosha processing it and allows 
a biased 3p strand loading onto Ago-2. On the other hand, the Dicer-independent 
pathway involves Drosha processing of the short hairpin RNA (shRNA) transcripts, 
but is too short to be cleaved by Dicer [21] Hence, the entire pre-miRNA is loaded 
onto the Ago-2, which slices the 3p strand. Finally, the trimming from 3′-5′ of the 5p 
strand concludes the maturation of the miRNA [14, 22].
3. Role of miRNAs in HSV replication
miRNAs play a huge role in the crosstalk between the virus and the host. There 
are certain viral and cellular miRNAs that regulate the host responses to a viral 
infection as well as the progression of infection. Both the viral and the cellular miR-
NAs are capable of regulating the host and the viral mRNAs. Some of the miRNAs 
that have been identified to be involved during the HSV-1 infection have a direct or 
indirect impact on the viral replication. These cellular miRNAs may directly target 
the HSV genome or are manipulated by the HSV through the viral proteome/tran-
scriptome [23] HSV-1 infected HeLa cells have shown a downregulation of the miR-
649 cellular miRNA that targets a ubiquitously expressed cytoplasmic protease, 
MALT-1, which activates the NF-κB signaling (Figure 2). Since NF-κB signaling 
inhibits HSV-1 replication, the downregulation of miR-649 elevates the expression 
of MALT-1, increasing the restriction on HSV-1 replication [24] Similarly, another 
cellular miRNA which is involved in the suppression of HSV-1 replication is miR-
101 (Figure 2). The HSV- viral immediate early protein ICP4 directly binds to the 
promoter of miR-101 to increase the expression of miR-101 in the infected cells 
thereby decreasing the expression levels of its target GRSP1, which is a scaffolding 
Figure 2. 
miRNAs in HSV replication: The figure describes the mode of action of the various cellular miRNAs (green) and 
the viral miRNAs (blue) that regulate the HSV replication. While the cellular miRNAs, miR-649, −101, −23a, −373  
and the viral miRNA, miR-H6 block the HSV replication, the cellular miRNA, miR-155 and the viral miRNA, 
H-27 promote the HSV viral replication. Both the viral and the cellular miRNAs regulate the host as well as 
the viral gene expression to modify the replication process either as a host response tying to fight the infection 
or to establish the infection within the host. Pointed arrowheads indicate progression of an event while blunt 




protein that may be involved in the polarization of epithelial cells. GRSP1 directly 
bind to the HSV-1 p40 and increases the replication of HSV-1. With enhanced 
suppression of GRSP1, the replication of HSV-1 is hindered. Although it seems 
surprising that HSV auto-downregulates its replication, it may be a necessary step 
for the virus to prevent host cell death due to lysis, therefore, maintaining a permis-
sive milieu for virus harboring and replication within the cells [25] Also, miR-101 
can target ATP5B, a subunit of the ATP synthase, to restrict the HSV-1 replication 
[26] These studies depict that a single miRNA such as miR-101 could regulate 
multiple targets to restrict the viral replication. In a study conducted by Shabani 
et al., a macrophage miR-7704, was capable of reducing the HSV-1 replication in 
HeLa cells [27] Another cellular miRNA, miR-23a which targets the Interferon 
regulatory factor-1 (IRF-1), involved in innate antiviral immunity, is upregulated, 
so as to escape the host immune responses [28] Also, a direct suppressor of IRF-1, 
miR-373, enhances HSV-1 replication by supressing the interferon stimulatory gene 
responses (Figure 2) [29] Increased expressions of miR-155, a miRNA which could 
epigenetically increase the transcription of the serine/arginine-rich splicing factor 
2 (SRSF2), enhances the HSV-1 replication, due to SRSF2- mediated transcriptional 
activation of the HSV-1 genes (Figure 2) [30] Some HSV-1 viral miRNAs have also 
been studied that regulate the virus’s replication. HSV-miR-H6, a viral miRNA 
which is generated profusely during HSV-1 infections, reduces HSV-1 replication by 
downregulating the viral protein ICP4 (Figure 2) [31] Also, H-27 targets KLHL24 
which is a transcriptional repressor (Figure 2). Therefore, increase in H-27 expres-
sion does not allow KLHL24 to suppress the HSV-1 immediate early and early gene 
expression, thus, promoting HSV-1 replication [23, 32].
4. miRNAs in acute HSV infection and latency
Encephalitis due to acute HSV-1 or − 2 infection could arise as a direct effect of 
the HSV invasion of the host or due to the heightened host responses to the virus 
which causes host damage in the process of virus destruction. Although the inci-
dence of Herpes Simplex Encephalitis (HSE) cases is low, 20% of those affected face 
neurological after-effects [23] The inflammation associated with encephalitis often 
involve the miRNAs, which is also the situation in HSE. miRNAs also contribute 
to the susceptibility of the cells to HSV infection. This may be the reason for the 
discovery of a number of cellular miRNAs in HSE. miRNAs miR-155, miR-146a 
and miR-15b were found to be upregulated in the mouse brain post-HSE [33] and 
have been associated with neuroinflammation (Figure 3) [34] HSV-1 encoded 
miR-H28 and miR-H29 were identified to be expressed late during the infection and 
are exported out of the infected cells in exosomes, thus indicating a role of these 
miRNAs in viral spread [35] Also, miR-200 family and miR-182 are the miRNAs 
identified to be involved in HSE as they target Syndecan-2 (sdc2) which contributes 
to the biosynthesis of the heparan sulphate required for the attachment and entry 
of HSV into the cells. Therefore, downregulation of sdc2 by miRNAs is a strategy 
maneuvered by the host to resist the spread of the virus [33] This also depicts that 
mutations in the miRNA sequence or the mRNA target are key players in varied 
susceptibility to the HSV infection of the central nervous system.
The opposite of excessive HSV pathogenesis is HSV latency, a phase of HSV 
infection characterized by minimum genome replication. HSV uses neurons as 
the hideaway for escaping the spotlight for the immune responses while sheltering 
itself within the host. Since the discovery of HSV- miRNAs in 2006, many miRNAs 
have been identified to participate in the different stages of viral latency [36] 
miR-LAT (Latency associated transcript), a miRNA generated from the exon 1 of 
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the HSV1-LAT gene, is responsible for the TGF-β mediated anti-apoptotic effects 
on the cells during latency. HSV-miR-H2 has been found to suppress the immediate 
early protein ICP0, therefore, inhibiting the replication to promote HSV latency 
(Figure 3) [37] On the other hand, HSV2-miR-H6, a miRNA associated with 
HSV2-LAT, contributes to the reactivation of the virus from latency [38] Mutation 
studies on both these miRNAs confirm their effects. miR-I, is another HSV2-LAT 
associated miRNA which reduces the expression of ICP34.5, a neurovirulence 
factor, to establish latency in the dorsal root ganglia [39] A similar study by the 
same group identified miR-II and miR-III miRNAs from the HSV2-LAT, with miR-II 
targeting ICP34.5 and miR-III targeting ICP0, to maintain latency (Figure 3) [40] 
Furthermore, the cellular miRNAs also engage in the events of HSV latency. miR-
155 is involved in the maintenance of latency via the elicitation of CD8 responses 
[41] Similarly, enhanced expression of miR-138 in the neurons, to target ICP0 for 
suppression (Figure 3), is crucial in maintaining the HSV-1 latency and survival 
of the hosts [42] The crosstalk between the viral/cellular miRNAs, amongst them-
selves, and with the host transcriptome decides for the maintenance of latency 
which may be for the lifetime, or trigger the reactivation of the virus.
5. Role of miRNAs in the immunological events of HSV infection
Ocular infection by HSV-1 may lead to chronic inflammation resulting in lesions 
of stromal keratitis (SK). The immunological events underlying the development of 
SK involve organized T-helper 1 (Th1) and T-helper-17 (Th17) cells, which produce 
IFN-γ and IL-17, respectively [43, 44]. Also, the involvement of the regulatory T 
cells (Treg) guides the exacerbation or abatement of the keratitis [45, 46] miRNAs 
also regulate the development, activation, function and recruitment of the Th and 
Figure 3. 
miRNAs in HSV latency: Majorly, the LAT-associated v-miRNAs participate in the induction, establishment 
and maintenance of latency of the HSV in the cells. HSV-miR-I and miR-II suppress the ICP34.5 expression 
to restrict HSV replication and promotion of the HSV latency. HSV-miR-H2 and miR-III inhibit the ICP0 
expression to suppress the HSV replication. HSV-miR-LAT inhibits apoptosis to allow the infected cell and the 
virus to survive and establish a latent infection. There are two cellular miRNAs that contribute to the latency. 
miR-138 promotes latency by preventing ICP0-triggered viral replication whereas miR-155 contribute to the 




the Treg cells [47] A pro-inflammatory miRNA, miR-155 is known to be upregu-
lated during SK and leads to the enhancement of the Th1 and Th17 responses and 
helps promoting the keratitis. Antagomir nanoparticles containing the anti-miR-155 
sequences have been shown to downregulate miR-155 expression and suppress 
SK [48] Also, miR-132 was found to be upregulated during SK, which helps in the 
advancement of angiogenesis via upregulation of the vascular endothelial growth 
factor (VEGF) by directly targeting a negative regulator of VEGF, a Ras-GTP 
inhibitor [49] The Toll-like receptor (TLR) pathway is an integral innate immune 
response pathway that is altered in almost all infection scenarios. Similarly, the 
genes associated with the TLR pathway are modulated post-HSV-2 infection by 
the miRNAs, miR-124, miR-150, miR-342-5p, miR-1245b-5p, miR-1245b-3p, and 
miR-592 [50] Speaking of the innate immune responses, type I Interferon (IFN) 
signal transduction plays a crucial role in curbing viral replication. Thus, for the 
virus to establish a progressive infection, it must manipulate the host machinery 
to overcome the IFN combat. So far, in case of HSV-1, miR-221 is manipulated by 
HSV-1 to suppress the IFN-β production and effector functions [51] The major 
innate immune response involved immediately after the HSV infection is the series 
of events resulting in acute inflammation, which is essential for virus clearance. 
This also implies that the infiltrates need to be resolved and the cell debris need 
to be cleared off so as to maintain the immunological homeostasis of the host, 
preventing a chronic inflammation that could be lethal [52] Certain pro-resolving 
mediators (SPMs) function to resolve the acute inflammatory state and may engage 
a few miRNAs to do so. The binding of Resolvin (RvD1), a SPM, to its receptor 
upregulates the miRNAs miR-21, miR-146b, miR-219, and downregulates miR-208a 
[53, 54] The target mRNA of miR-219 is the transcript of the gene encoding the 
5-lipoxygenase enzyme that leads to the decreased production of leukotriene B4 
and increased production of the SPMs. miR-146b suppresses the expressions of 
IL-8 and RANTES, which are the leucocyte-recruiting chemokines at the inflamed 
regions [54]. miR-146a is also pro-inflammatory in nature and have been shown 
to trigger the arachidonic acid-mediated, overproduction of IL-1β, to induce an 
Alzheimer’s-like neuropathological condition in the brain. Since it can directly 
suppress the complement factor H, it is considered as one of the mechanisms of 
complement evasion by HSV-1 [55] Another miRNA upregulated as a result of RvD1 
binding is miR-21 which contributes to the establishment of an anti-inflammatory 
milieu by increasing the production of IL-10 when the resolution of inflammation 
is vital [56, 57] Contradictorily, miR-208a, which decreases the IL-10 production 
and enhances the NFκB activation to prolong the inflammatory events, was itself 
constrained [54]. It has also been noted that miRNAs can function in a cell/tissue-
specific manner. miR-4661 is one such miRNA that promotes acute inflammation in 
the neutrophils, whereas mediates the cessation of the inflammatory responses in 
the monocytes and the macrophages via the augmented production of SPMs. It also 
polarizes the macrophages towards the resolution of inflammation [58] HSV-1 miR-
H8 reduces natural killer (NK) cell- dependent killing of the virus-infected cells 
by the suppression of the glycosylphosphatidylinositol gene expression [59] HSV-1 
viral miR-H28 induces the production of IFN-γ also to restrict the spread of HSV-1 
between cells while not affecting the viral replication, so that optimal transmission 
between individuals take place [60].
6. Other herpesviridae viral miRNAs
The herpes simplex virus 1 and 2 discussed mainly in this chapter are also 
termed as human herpesvirus (HHV)-1 and 2. The other members of the 
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herpesviridae family of viruses include the Varicella zoster virus (VZV) or HHV-3, 
the Epstein Barr virus (EBV) or HHV-4, the human cytomegalovirus (HCMV) or 
HHV-5, the Roseoloviruses HHV-6 and HHV-7, and the Kaposi’s sarcoma-associated 
herpesvirus (KSHV) or HHV-8 [61] A common characteristic of the herpesviruses 
is that all the members are capable of establishing latent infections in their hosts 
and reactivate when the immune system has been compromised. Herpesvirus 
reactivation brings about changes in the host signaling pathways with the help of 
alterations in the miRNA expression [62] VZV is a neurotropic virus that causes 
chickenpox in humans. Although there are not many reports on VZV v-miRNAs, 
nearly 20 miRNAs have been predicted from the VZV genome and some of these 
miRNAs have been shown to be involved in viral replication [63, 64] EBV, the first 
human oncovirus reported to encode viral miRNAs and cause various cancers such 
as nasopharyngeal carcinoma and Burkitt’s lymphoma, encodes 44 miRNAs. The 
EBV miRNAs target the viral as well as the host mRNAs to regulate carcinogenesis 
and cellular transformation of the EBV-associated cancers [65] HCMV, which allows 
extensive replication in the endothelial as well as the epithelial cells and has a large 
dsDNA genome of 230 bp, encodes 22 miRNAs [66, 67] KSHV, a gamma herpes-
virus and the causative agent of Kaposi’s sarcoma, encodes 25 miRNAs. The family 
also contains HHV-6 and HHV-7, which are the lesser explored members. A single 
miRNA, miR-U86, encoded by HHV-6A has been reported to target the expression 
of the U86 gene which is an IE gene of HHV-6A [68] Therefore, apart from HSV-1 
and HSV-2, the other members of the herpesviridae family also encode a number of 
miRNAs to regulate their infection cycles in the host. Owing to similarities amongst 
them, investigations pertaining to one will provide insights regarding the other. 
Here, we discuss some of the miRNA effector functions that are employed during 
other herpesvirus infections.
6.1 The human cytomegalovirus (HCMV) miRNAs
The HCMV have co-evolved with their hosts and encoding miRNAs that are 
capable regulators of cell cycle progression, viral gene expression, apoptosis and 
host immune response evasion (Figure 4). In order to maintain the latent infection, 
the virus attempts to maintain the hematopoietic progenitor cells (HPCs) in the 
dormant state. EGR-1 (Early growth response gene-1) is critical in maintenance 
of the HPC quiescence. miR-US22 is a HCMV miRNA that is expressed during the 
early infection stages or reactivation to restrict the proliferation of the HPCs. It does 
so by targeting the host transcription factor, EGR-1, so that the HCMV can overtake 
the host replication machinery for its own replication. Since viral replication is 
close to negligible during latency, the HCMV miR-US22 is not expressed during 
this state [69] Another miRNA mechanism to limit cell proliferation during latency 
is the suppression of the RhoA, a regulator of the actin dynamics. miR-US25–1 
targets the RhoA GTPase to disable mitosis in the cells [66, 67] The lytic and latent 
infections are characterized by the abundant expression of the miRNAs, miR-
US25–1, miR-UL112-3p, and miR-UL22A. Although most of the HCMV miRNAs 
are detected during the first 4 hours of infection, miR-UL22A, miR-UL112-3p and 
miR-UL148D continue to be detected post-IE infection. miR-UL112-3p targets the 
UL123 viral mRNA that codes for IE72 which is actively involved in viral replication 
and cell lysis [70] miR-UL148D targets the IE response 5 transcript to indirectly 
regulate the expression of the viral IE genes through the signaling transduc-
tion events induced by Cyclin-dependent kinase 1 (CDK-1) in order to promote 
latent HCMV infections [71] The FOXO transcription factors are the facilitators 
of both mitochondria-dependent and -independent pathways for the induction 




to target a member of the FOXO family, FOXO3a [73] The mechanism involves a 
downregulation of FOXO3a expression such that its pro-apoptotic functions are 
limited and binding to the promoter of Bcl-2-like protein 11 (Bim) is restricted. 
In profusely HCMV replicating cells, the IKK expression was directly constrained 
by the miR-US5–1 and miR-UL112-3p miRNAs of HCMV, such that production of 
the pro-inflammatory cytokines, IL-6 and RANTES via the NF-κB pathway was 
considerably suppressed [74] miR-UL148D directly targets the RANTES transcript 
to suppress its pro-inflammatory functions [75] Also, miRUL112-3p directly targets 
MICB, an MHC I-related chain B, to indirectly repress the NK-cell killing activity so 
as to protect the infected cells from destruction during the lytic and preferably also 
during the latent HCMV infections [66, 67, 76].
6.2 Kaposi’s sarcoma (KS)- associated herpesvirus (KSHV) miRNAs
KSHV miRNAs regulate the viral mRNAs directly as well as indirectly via the 
regulation of the cellular mRNAs (Figure 4). Certain viral miRNAs participate 
to establish latency in the KSHV-infected cells. miR-K7 and miR-K9–5p target the 
KSHV RTA protein, which acts as a switch between the lytic and latency cycles 
[77, 78] Also, miR-K11 and miR-K3 function to maintain latency by indirectly sup-
pressing the RTA transcript [79–81] Another latency-inducing miRNA is the miR-
K4-5p which inhibits the retinoblastoma-like protein-2 (RBl2) expression due to 
which the DNMT1 (methylation enzyme) expression increases. Methylation of the 
RTA promoter by DNMT1 suppresses RTA expression, inducing latency in the cells 
[79, 81] Angiogenesis is an important event in the KSHV infection as it allows the 
spread of the latency-induced malignancies. GRK2 which regulates the AKT/CXCR2 
pathway to establish a reciprocity between viral replication and induction of angio-
genesis, is targeted by miR-K3 to decrease viral replication and induce angiogenesis, 
thus establishing latency [82] Contradictorily, BCLAF1, Bcl 2-associated factor-1, 
is the common target for miR-K5, miR-K9 and miR-K10a/b and has been known to 
Figure 4. 
miRNAs in other herpesvirus infections: The figure summarizes the involvement of the various miRNAs in the 
different events of other herpesvirus infection. Here, we have taken the example of two herpesviruses, HCMV 
(navy blue) and KSHV (magenta) to show the extent of v-miRNA involvement during the viral pathogenesis. 
Mostly, the viral miRNAs involved in replication, latency, cell survival and immune modulation have been 
mentioned in the figure and are the ones widely explored.
Viral Outbreaks
10
trigger the lytic infection cycle [83] miR-K5 and K9 also suppress the TLR-mediated 
production of the inflammatory cytokines IL-6, IL-8 and IL-1α by directing inter-
fering with the intermediates, MyD88 and IRAK-1, respectively [84, 85] The KSHV 
miRNAs also attempt to inhibit apoptosis and promote cell survival, which is crucial 
for both malignancy and latency. Therefore, miR-K1, -K3 and -K4 inhibit apoptosis 
by directly targeting the Caspase-3 protease [86] miR-K10, the viral orthologue of 
hsa-miR-142-3p, targets TGF-β to promote cell survival and cellular transformation 
[87, 88] miR-K10a is also the negative regulator of the TWEAK receptor, which is 
the receptor for the TNF-like weak inducer of apoptosis, thereby, inhibiting apopto-
sis as well as downregulating the production of IL-8 and MCP-1 to contribute to the 
KS progression [89] miR-K1 also promotes cell cycle progression by inhibiting p21 
[90] Another target for miR-K1, IκBα, which usually retains NF-κB in the cytoplasm 
by blocking the nuclear localization signals, is constrained to promote latency and 
survival of the transformed cells [91] Activation of NF-κB also inhibits the Warburg 
effect leading to the declined expressions of GLUT-1 and GLUT-3, suggesting the 
significance of the metabolic regulation for the proliferation of the KS cells [92] 
Just as miR-155 have been considered as the regulatory epicenter of various cancers 
and viral infections, the KSHV miRNA, miR-K11 mimics some of the functions of 
this cellular miRNA. miR-K11 blocks the C/EBPβ resulting in the enhanced, IL-6-
mediated proliferation of the B cells [93] It also targets JARID2 leading to increased 
B cell transformation [94] Moreover, miR-K11 also inhibits the IFN type I signaling 
by directly targeting IKKε mRNA [95, 96] Thus, the generation of cellular miRNA 
orthologues by the herpesviruses is clearly evident of its co-evolution with its host, 
such that it diverts the cellular machinery towards its own viral processes while 
hiding itself efficiently from the host responses.
7. miRNAs as potential biomarkers in herpesvirus infections
With as many miRNAs that are expressed during each of the herpesvirus 
infections, the recognition of certain miRNAs are biomarkers for these infections 
is promising. There are a number of reasons that back the concept of miRNA 
biomarkers in human infections. The distinct pathophysiological events occurring 
during the infection is reflected in the miRNA expression patterns. For example, 
where miR-649 is considerably downregulated in HSV-1 infected cells as compared 
to the uninfected cells to mark the overwhelming participation of NF-κB is fight-
ing the infection, there are certain miRNAs exclusively generated by the HSV 
(miR-H6, -H27 etc.). miRNAs are also the biomarkers of the HSV infection status 
within the host as certain miRNAs are specific to the lytic phase (miR-H1) whereas 
some are specifically expressed during the latency phase (miR-H2–6). miRNAs are 
easily available for detection in the body fluids such as blood, serum and human 
dental pulps [97, 98] and so are the v-miRNAs of the herpesviridae family members 
[99] Although there are a few ongoing clinical studies on miRNAs biomarkers in 
cancer, the reports on EBV-related cancer miRNAs also being detected in the blood 
and urine, will boost the EBV research in the same direction [100] Furthermore, 
the molecular techniques used for the miRNA detection, such as, the real-time 
PCR array, microarray profiling and the next-generation sequencing techniques 
are popular and well established in case of herpesvirus infections as well [101–104] 
One of the greatest advantages of using miRNAs as biomarkers is their sustained 
expressions in vivo as compared to the mRNAs. This is because of the presence of 
exosomes which enclose the miRNAs. Moreover, the miRNAs released extracellu-
larly are bound to the Ago proteins. These mechanisms protect the miRNAs against 




are better biomarker candidates might be debatable. However, an important con-
sideration in this context is that v-miRNAs are virus-specific whereas host miRNAs 
are not exclusive for a virus infection. For example, miR-155, which is crucial in 
HSV-1 latency is also involved in pro-inflammatory functions in other diseases 
such as cancer, asthma, arthritis, Cystic fibrosis and also recently reported in other 
viral infections, such as that of the Sars-CoV-2 [41, 107, 108] Therefore, a panel of 
host and viral miRNA combinations may serve as an appropriate biomarker in case 
of each of the herpesvirus infection.
8. Therapeutic considerations of miRNAs in herpesvirus infection
miRNAs can also be referred to as the endogenous post-transcriptional gene 
regulators and have a special advantage over drugs. miRNAs are self-molecules 
and hence are safer than any of the synthetic or natural compounds used as 
therapeutics against the infections. Another feature of miRNAs that make them 
interesting candidates for therapeutic considerations is their ability to regulate 
more that one gene expression, and inversely, the expression of a single gene can 
be modulated by more than one miRNA. Being the regulators of gene expression, 
modification of the miRNAs is an approach for changing the course of an infection 
or a disease. There are two ways by which the miRNA expression may be modified. 
One of modifications include reintroduction of the miRNA expressions by the use 
of specific miRNA mimics, while the second is to block the infection-induced/
modified miRNA expression by the use of the specific-miRNA inhibitors [23] The 
use of miRNA mimics and inhibitors have been trending in the field of research 
on infectious diseases since the successful progression of miRavisen through the 
clinical trials to be established as therapeutics against the Hepatitis C virus [109] 
miRavisen is a miRNA inhibitor of miR-122, a miRNA which increases the HCV 
viral replication [110, 111] Similarly, inhibitors of miR-373 or HSV-miR-H27 can be 
administered as therapeutics to decrease the HSV viral load in the hosts. There have 
also been studies where mimics of miRNAs have proved to be useful in restricting 
viral replication. Recently, a study identifying the significance of miR-29b mimics 
have been reported to decrease the Rotavirus infection considerably [112] Likewise, 
mimics of miR-7704 and miR-101 could be encouraged in the HSV therapeutic 
research. Furthermore, the reported miRNA research could be compiled to develop 
therapeutic formulations involving combinations of mimics and inhibitors to syner-
gistically suppress the HSV infection in the host. However, miRNAs, like any other 
therapeutics, face the challenges of target-specific delivery and off-target effects. 
These challenges are also being addressed by the researchers with the synthesis of 
appropriate miRNA-loaded nanoparticles which ensures on-site targeted delivery 
and optimal bioavailability while maximally reducing the off-target effects [6] 
All-in-all, the potentiality of miRNAs as therapeutic agents against viral infections 
is being explored explicitly, also implying that their clinical applications in herpes-
virus infections is inevitable.
9. Conclusion
Elucidation of miRNAs have emerged as a promising field of research due to 
the capability of the miRNAs to be easily manipulated to alleviate an infection. The 
fact that a single miRNA can target more than one gene expression (viral, cellular, 
or both) to suppress the viral infection is equally fascinating and efficient. The 
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them acceptable to the researchers. All the more, the commercially available mimics 
and inhibitors of the miRNAs makes the research pertaining to them affordable. 
However, miRNAs face the challenges of specific, on-site delivery, long-term 
miRNA stability and off-target consequences, and yet, have been FDA-approved 
under the small molecule therapeutics category. The challenges of targeted delivery 
and optimum bioavailability is met with the miRNA-loaded nanoparticles, which 
diminish the off-target effects as well. Thus, with miRNAs finding their utility into 
a variety of applications, expansion of the miRNA investigations, both in basic and 
applied research, is evident.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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